Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma.

Kim JH, Kim WS, Park C.

Leuk Lymphoma. 2013 Sep;54(9):2035-40. doi: 10.3109/10428194.2013.769218. Epub 2013 Feb 28.

PMID:
23363221
2.

Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1.

Kim JH, Kim WS, Kang JH, Lim HY, Ko YH, Park C.

FEBS Lett. 2007 Feb 20;581(4):623-8. Epub 2007 Jan 18.

3.

Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner.

Tao YG, Tan YN, Liu YP, Song X, Zeng L, Gu HH, Tang M, Li W, Yi W, Cao Y.

Cell Signal. 2004 Jul;16(7):781-90.

PMID:
15115657
4.

Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth.

Tobollik S, Meyer L, Buettner M, Klemmer S, Kempkes B, Kremmer E, Niedobitek G, Jungnickel B.

Blood. 2006 Dec 1;108(12):3859-64. Epub 2006 Aug 1.

6.

Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression.

Johansson P, Jansson A, Rüetschi U, Rymo L.

J Virol. 2009 Feb;83(3):1393-401. doi: 10.1128/JVI.01637-08. Epub 2008 Nov 19.

7.

Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway.

Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M.

Nucleic Acids Res. 2008 Nov;36(20):6608-19. doi: 10.1093/nar/gkn666. Epub 2008 Oct 21.

8.

Regulation of the MIR155 host gene in physiological and pathological processes.

Elton TS, Selemon H, Elton SM, Parinandi NL.

Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Review.

PMID:
23246696
9.
10.

Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway.

Dudziak D, Kieser A, Dirmeier U, Nimmerjahn F, Berchtold S, Steinkasserer A, Marschall G, Hammerschmidt W, Laux G, Bornkamm GW.

J Virol. 2003 Aug;77(15):8290-8.

11.

NF-κB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma.

Chen CC, Liu HP, Chao M, Liang Y, Tsang NM, Huang HY, Wu CC, Chang YS.

Oncogene. 2014 Jul 10;33(28):3648-59. doi: 10.1038/onc.2013.345. Epub 2013 Aug 26.

PMID:
23975427
12.

Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.

Larcher C, Bernhard D, Schaadt E, Adler B, Ausserlechner MJ, Mitterer M, Huemer HP.

Haematologica. 2003 Dec;88(12):1324-35.

13.

Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.

Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, Rowe M, Woodman CB, Murray PG.

J Pathol. 2013 Aug;230(4):399-409. doi: 10.1002/path.4198.

PMID:
23592216
14.

The latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus induces expression of the putative oncogene Bcl-3 through activation of the nuclear factor-kappaB.

Nakamura H, Ishii C, Suehiro M, Iguchi A, Kuroda K, Shimizu K, Shimizu N, Imadome K, Yajima M, Fujiwara S.

Virus Res. 2008 Feb;131(2):170-9. Epub 2007 Oct 25.

PMID:
17963943
15.

Epstein-Barr virus latent membrane protein 1 induces CD69 expression through activation of nuclear factor-κB.

Ishikawa C, Mori N.

Int J Oncol. 2013 May;42(5):1786-92. doi: 10.3892/ijo.2013.1871. Epub 2013 Mar 28.

PMID:
23546309
16.

A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways.

Adriaenssens E, Mougel A, Goormachtigh G, Loing E, Fafeur V, Auriault C, Coll J.

Oncogene. 2004 Apr 8;23(15):2681-93. Erratum in: Oncogene. 2004 Oct 21;23(49):8184.

PMID:
14767477
17.

Transactivation of CCL20 gene by Epstein-Barr virus latent membrane protein 1.

Okudaira T, Yamamoto K, Kawakami H, Uchihara JN, Tomita M, Masuda M, Matsuda T, Sairenji T, Iha H, Jeang KT, Matsuyama T, Takasu N, Mori N.

Br J Haematol. 2006 Feb;132(3):293-302. Retraction in: Br J Haematol. 2011 Mar;152(6):787.

PMID:
16409294
18.

Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations.

Epeldegui M, Hung YP, McQuay A, Ambinder RF, Martínez-Maza O.

Mol Immunol. 2007 Feb;44(5):934-42. Epub 2006 May 26.

PMID:
16730063
19.

Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes.

Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G, Bergamin S, Rizzo S, Dolcetti R, De Rossi A.

J Virol. 2008 Oct;82(20):10175-87. doi: 10.1128/JVI.00321-08. Epub 2008 Aug 6.

20.

Overexpression of Activation-Induced Cytidine Deaminase in MTX- and Age-Related Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Disorders of the Head and Neck.

Kikuchi K, Ishige T, Ide F, Ito Y, Saito I, Hoshino M, Inoue H, Miyazaki Y, Nozaki T, Kojima M, Kusama K.

J Oncol. 2015;2015:605750. doi: 10.1155/2015/605750. Epub 2015 Mar 5.

Supplemental Content

Support Center